
NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target
NRX Pharmaceuticals (NRXP) Analyst Ratings
Bulls say
NRX Pharmaceuticals is supported by a meaningful regulatory inflection after FDA approval of KETAFREE, a preservative-free, U.S.-manufactured ketamine product that addresses the benzethonium chloride issue and can leverage proprietary blow-fill-seal packaging. The company is transitioning from clinical-stage to commercial stage with about 5 million launch units in process and anticipated capacity of 1 million units per month, while management’s 2026 revenue estimate of $5 million and 2027 estimate of $60 million appears conservative relative to the launch potential. Its larger upside thesis rests on NRX-100 and NRX-101, which target bipolar depression with suicidality in a market with no approved medicine, backed by existing clinical data, FDA filing progress, and potential approvals in 2027.
Bears say
NRX Pharmaceuticals is a clinical-stage developer with a fragile financial profile, as its Q2 2026 revenue was only $1.1 million versus expectations of $3.0 million to $16.6 million, underscoring weak commercialization and limited near-term operating traction. The company’s $16.5 million net loss, or $(0.44) per share, also came in worse than the $(0.13) to $0.06 range, highlighting continued cash burn and poor earnings visibility. With no company guidance and only nascent HOPE business revenue beginning in Q3 2025, the fundamental case remains challenged by high execution risk and a still-developing revenue base.
This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction
Start investing in NRX Pharmaceuticals (NRXP)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About NRX Pharmaceuticals (NRXP) Forecast
NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction
Start investing in NRX Pharmaceuticals (NRXP)
Order type
Buy in
Order amount
Est. shares
0 shares